The history and future of targeting cyclin-dependent kinases in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer is characterized by uncontrolled cell division, making cell cycle regulators like cyclin-dependent kinases (CDKs) attractive therapeutic targets.
• CDKs, particularly CDK4/6, CDK1, and CDK2, are crucial for cell cycle progression, and their dysregulation is implicated in tumorigenesis.
• Despite the strong rationale, developing effective CDK inhibitors for cancer treatment has faced historical challenges, with many early agents showing disappointing clinical results.

Purpose of the Study:

• To review the fundamental biology of CDKs in the context of cancer.
• To analyze the therapeutic rationale for targeting specific CDK complexes.
• To discuss the historical clinical outcomes of CDK inhibitors and highlight recent advancements.

Main Methods:

• Review of existing literature on CDK biology and cancer.
• Analysis of historical clinical trial data for CDK inhibitors.
• Discussion of emerging strategies in CDK inhibitor development and application.

Main Results:

• Targeting CDK4/6 complexes in the G1 phase is a key strategy due to their role in proliferation.
• CDK1 and CDK2 are also implicated in tumorigenesis through effects on chromosomal stability and cell cycle control.
• Early CDK inhibitors faced challenges, but newer agents with high selectivity, especially for CDK4/6, show improved clinical activity.
• Patient stratification strategies are crucial for enhancing the efficacy of CDK inhibitors.

Conclusions:

• Selective inhibition of CDKs, particularly CDK4/6, represents a viable therapeutic strategy for certain cancers.
• Combining selective CDK inhibitors with patient stratification has led to more significant clinical benefits.
• Further research into CDK biology and inhibitor development holds promise for advancing cancer therapy.